Abstract

This Technical and Technology Review from the European Society of Gastrointestinal Endoscopy (ESGE) represents an update of the previous document on the technical aspects of endoscopic ultrasound (EUS)-guided sampling in gastroenterology, including the available types of needle, technical aspects of tissue sampling, new devices, and specimen handling and processing. Among the most important new recommendations are:

ESGE recommends end-cutting fine-needle biopsy (FNB) needles over reverse-bevel FNB or fine-needle aspiration (FNA) needles for tissue sampling of solid pancreatic lesions; FNA may still have a role when rapid on-site evaluation (ROSE) is available.

ESGE recommends EUS-FNB or mucosal incision-assisted biopsy (MIAB) equally for tissue sampling of subepithelial lesions ≥20 mm in size. MIAB could represent the first choice for smaller lesions (<20 mm) if proper expertise is available.

ESGE does not recommend the use of antibiotic prophylaxis before EUS-guided tissue sampling of solid masses and EUS-FNA of pancreatic cystic lesions.

Background

Benign colorectal resections are performed to address a spectrum of non-oncological conditions, including but not limited to diverticulitis, inflammatory bowel disease (IBD), polyposis coli, functional bowel disorders, and endometriosis. While the surgical procedure mirrors that of oncological cases, the primary distinction lies on the preservation of a greater portion of the mesentery in these non-oncological resections. Nevertheless, irrespective of the underlying condition, any type of colorectal resection could have an adverse impact on the patient's bowel function.